obesity tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification? Tirzepatide for Obesity Treatment and

When food enters the digestive system, specialised cells in the gut release GLP-1, which stimulates insulin secretion, slows gastric emptying, and promotes feelings of satiety

Kinetics and mechanisms of reactions catalyzed by immobilized lipases

On-site solvent reprocessing: Some manufacturers are going beyond localized rinse reuse by installing on-site distillation or purification systems that enable full-scale, closed-loop solvent recycling

Technical Remarks When CGM is used in individuals with pre-existing diabetes, providers and patients should use fasting and postprandial glucose targets (whether measured by CGM or SMBG) as the basis for insulin adjustment and not a single glucose target of 63140 mg/dL When using CGM in conjunction with HCL, providers should be aware that not all HCL algorithms can meet these targets This recommendation applies to all types of pre-existing diabetes, including type 1 diabetes and type 2 diabetes There are limited data on the appropriate lower limit of the target for fasting or postprandial glucose in pregnancy

PlexusDx offers patients the option to understand their genetic predispositions in GLP-1 and related peptide pathways through the Precision Peptide Genetic Test, which may help provide context for informed conversations with providers about whether medication, dietary optimization, or combination approaches align with individual genetics and clinical goals